Barclays
ATOS icon

Barclays’s Atossa Therapeutics ATOS Stock Holding History

Barclays’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,251
Closed -$15.6K – 5478
2025
Q2 		$15.6K Sell
1,251
-7,321
-85% -$87.5K ﹤0.01% 4867
2025
Q1 		$86.5K Sell
8,572
-4,225
-33% -$51.3K ﹤0.01% 4458
2024
Q4 		$181K Buy
12,797
+1,616
+14% +$31.6K ﹤0.01% 4360
2024
Q3 		$255K Buy
11,181
+8,245
+281% +$166K ﹤0.01% 4174
2024
Q2 		$52.4K Buy
+2,936
New +$65K ﹤0.01% 4193
2022
Q3 		– Sell
-7
Closed – – 4778
2022
Q2 		$0 Sell
7
-1,266
-99% -$19.9K ﹤0.01% 5013
2022
Q1 		$24K Sell
1,273
-8,194
-87% -$166K ﹤0.01% 4388
2021
Q4 		$227K Buy
9,467
+6,280
+197% +$230K ﹤0.01% 3519
2021
Q3 		$156K Buy
3,187
+1,649
+107% +$95.9K ﹤0.01% 3733
2021
Q2 		$145K Sell
1,538
-2,842
-65% -$150K ﹤0.01% 3688
2021
Q1 		$139K Buy
4,380
+3,592
+456% +$131K ﹤0.01% 3866
2020
Q4 		$11K Hold
788
– – ﹤0.01% 4741
2020
Q3 		$29K Buy
+788
New +$37.8K ﹤0.01% 4810
2019
Q4 		– Sell
-3
Closed – – 6332
2019
Q3 		$0 Sell
3
-367
-99% -$11.6K ﹤0.01% 6696
2019
Q2 		$14K Sell
370
-112
-23% -$4.49K ﹤0.01% 6483
2019
Q1 		$25K Sell
482
-1,677
-78% -$48.9K ﹤0.01% 6259
2018
Q4 		$33K Buy
+2,159
New +$42.7K ﹤0.01% 5680
2018
Q2 		– Sell
-895
Closed -$72K – 6954
2018
Q1 		$72K Buy
+895
New +$83.4K ﹤0.01% 5617
2017
Q2 		– Sell
-11
Closed -$2K – 6625
2017
Q1 		$2K Buy
+11
New +$2.81K ﹤0.01% 6447
2013
Q3 		– Sell
-1
Closed -$14K – 7391
2013
Q2 		$14K Buy
+1
New +$16.9K ﹤0.01% 6982

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Barclays's ATOS Position: Q3 2025 in Review

Barclays sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 1,251 shares — an estimated $15.6K sold.

Barclays first reported a position in ATOS in Q2 2013 and held it in 20 quarters. The position peaked at $255K in Q3 2024. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Barclays reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 1,251 Atossa Therapeutics shares in Q3 2025, an estimated $15.6K.
  • Barclays first reported a position in Atossa Therapeutics in Q2 2013 and held it in 20 quarters.
  • Barclays's Atossa Therapeutics position peaked at $255K in Q3 2024.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.